ClinicalTrials.gg
CompletedNCT02503332FILLYUpdated Oct 6, 2020Results posted

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

A Phase 2 interventional study of Pegcetacoplan and Sham Procedure in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 46 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
35th of 107
246 · median 98
Started
2015
with 5 others
Phase 2
43 of 131
11 open now
Registered
41st of 131
by date
Lead sponsor
8 of 131
Apellis Pharmaceuticals, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 35th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2015, is one of 43 in phase 2, and was the 41st registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).

Read the detailed description

This is a Phase II, prospective, multicenter, randomized, single-masked, sham-controlled study to assess the safety, tolerability and evidence of activity of multiple IVT injections of pegcetacoplan in subjects with GA secondary to Age-Related Macular Degeneration.

The study will randomize approximately 240 subjects to obtain at least 200 evaluable subjects across 40 multinational sites.

Subjects will be randomized in a 2:2:1:1 manner to receive pegcetacoplan Monthly (AM), pegcetacoplan Every-Other-Month (AEOM), Sham injection Monthly (SM) or Sham injection Every-Other-Month (SEOM), respectively.

All subjects will return to the clinical site on Day 7 to assess acute safety after the first injection. After that, subjects in the monthly groups will return to the clinical site for additional pegcetacoplan (or Sham) injections and study procedures every month until Month 12. Subjects in the Every-Other-Month groups will return to the clinical site for additional pegcetacoplan (or Sham) injections and study procedures every two months until Month 12. All subjects will return for follow-up visits on Months 15 and 18 (3 and 6 months after last injection, respectively).

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to the study eye only.

  1. Male or Female.
  2. Age greater than or equal to 50 years.
  3. BCVA of 20/320 (Snellen equivalent) or better using ETDRS charts.
  4. Diagnosis of GA of the macula secondary to age-related macular degeneration, confirmed within 14 days prior to randomization by the central reading center (CRC) using Fundus Autofluorescence (FAF) images, as well as the following criteria:

    1. Total GA area must be ≥ 2.5 and ≤ 17.5 mm2 (1 and 7 disk areas [DA] respectively), determined by screening images of FAF.
    2. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA).
    3. GA can be completely visualized on the macula centered image.
    4. GA must be able to be photographed in its entirety.
    5. GA must be able to be measured separately from any areas of peripapillary atrophy as assessed by the CRC.
    6. Presence of any pattern of hyperautofluorescence in the junctional zone of GA. Absence of hyperautoflouorescence (i.e. pattern = none) is exclusionary. See Holz et al. 2007.1
  5. Female subjects must be:

    1. Women of non- (WONCBP), or
    2. Women of child-bearing potential (WOCBP) with a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study.
  6. Males with female partners of child-bearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study.
  7. Willing and able to give .

Exclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply to the study eye only.

  1. GA due to causes other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like plaquenil maculopathy.
  2. Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >26 mm.
  3. Any history or current evidence of exudative ("wet") AMD including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere in the retina based on fluorescein angiogram as assessed by the CRC.
  4. Retinal disease other than AMD; however, benign conditions of the vitreous or peripheral retina are not exclusionary (i.e. pavingstone degeneration).
  5. Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator interferes with ophthalmologic examination (e.g. advanced cataract or corneal abnormalities).
  6. Any ophthalmologic condition that prevents adequate imaging of the retina judged by the site or CRC.
  7. Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.
  8. Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also excluded unless it occurred as a result of yttrium aluminum garnet (YAG) laser posterior capsulotomy in association with prior posterior chamber intraocular lens implantation and at least 60 days prior to Day 0.
  9. Any ophthalmic condition that may require surgery during the study period.
  10. Any to IVT injection including current ocular or periocular infection.
  11. History of uveitis or endophthalmitis.
  12. History of IVT injection at any time.
  13. Participation in another interventional clinical study, or use of any experimental treatment for AMD or any other new drug within 6 weeks or 5 half-lives of the active (whichever is longer) prior to the start of study treatment. Note: clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
  14. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the treatment period unlikely, or in general a poor medical risk because of other systemic diseases or active uncontrolled infections.
  15. Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the Investigator is and not suitable for study participation.
  16. to fluorescein.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan 15 mg/100 µL Monthly for 12 months

    A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.

    Drug: Pegcetacoplan

  • Experimental
    Pegcetacoplan 15 mg/100 µL EOM for 12 months

    A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.

    Drug: Pegcetacoplan

  • Sham comparator
    Sham Monthly for 12 months

    Subjects will receive a Sham procedure every month for 12 consecutive months.

    Other: Sham Procedure

  • Sham comparator
    Sham EOM for 12 months

    Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.

    Other: Sham Procedure

Interventions

06

What researchers measure

Primary outcomes

  1. Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12

    The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 12.

  2. Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity

    A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.

    Time frame: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).

Secondary outcomes

  1. LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12

    The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) and Month 12.

  2. LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12

    The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

    Time frame: Baseline (Day 1) and Month 12.

  3. LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12

    The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

    Time frame: Baseline (Day 1) and Month 12.

  4. LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12

    The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.

    Time frame: Baseline (Day 1) and Month 12.

  5. LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12

    The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) and Month 12.

  6. Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye

    The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.

    Time frame: From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).

07

Results

Posted Oct 6, 2020

Participant flow

This Phase II, randomized, single-masked, sham injection-controlled study in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) was conducted at 47 sites (46 active) in 3 countries between 24 September 2015 and 14 July 2017 (Data cut-off date, Month 12).

Participant flow — Overall Study
MilestonePegcetacoplan MonthlyPegcetacoplan EOMSham MonthlySham EOM
Started86794140
Completed52603336
Not completed341984
Withdrew: Adverse event17531
Withdrew: Investigator's decision5100
Withdrew: Sponsor's decision1001
Withdrew: Subject request6521
Withdrew: Death0220
Withdrew: Other5611

Outcome measures

PrimaryLeast Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12

The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 12.
Reported as:
Least squares mean · mm
Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12
mmPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 120.26 ± 0.0250.28 ± 0.0260.35 ± 0.025
PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity

A TEAE was defined as any adverse event (AE) that commenced or worsened on or after time of first study drug administration up to 60 days beyond last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possibly related or probably related or not reported. Severity of TEAEs were categorized as mild; moderate; severe; life-threatening or death related to TEAE, according to Common Terminology Criteria for AEs v4.03. A TEAE of special interest (TEAESI) was defined as a TEAE of scientific and medical concern specific to pegcetacoplan, whether serious or non-serious.

Time frame:
From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
ParticipantsPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
TEAEs654742
Treatment-related TEAEs21110
Serious TEAEs421
TEAEs with mild intensity363028
TEAEs with moderate intensity231411
TEAEs with severe intensity633
TEAEs with life-threatening intensity000
Death related to TEAEs000
TEAESIs540
TEAEs leading to study/treatment discontinuation1953
SecondaryLS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12

The untransformed area of GA was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) and Month 12.
Reported as:
Least squares mean · mm^2
LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 12
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Untransformed GA Lesion Size in the Study Eye at Month 121.49 ± 0.1611.69 ± 0.1682.12 ± 0.161
SecondaryLS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12

The BCVA letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

Time frame:
Baseline (Day 1) and Month 12.
Reported as:
Least squares mean · ETDRS letter score
LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12
ETDRS letter scorePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score of the Study Eye at Month 12-3.31 ± 1.352-5.78 ± 1.398-4.36 ± 1.364
SecondaryLS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12

The LL-BCVA was measured by placing a 2.0-log-unit neutral density filter over the best correction and having the participant read the normally illuminated ETDRS chart. The score ranges from 0 to 100 letters, lower number indicating worse vision; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.

Time frame:
Baseline (Day 1) and Month 12.
Reported as:
Least squares mean · ETDRS letter score
LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12
ETDRS letter scorePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Low Luminance BCVA (LL-BCVA) Score in the Study Eye at Month 12-2.73 ± 1.145-3.21 ± 1.184-0.55 ± 1.150
SecondaryLS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12

The LL-VA deficit score is calculated as BCVA score minus LL-BCVA score. The LL-VA deficit score ranges from 0 to 100 letters, lower number indicating worse deficit.

Time frame:
Baseline (Day 1) and Month 12.
Reported as:
Least squares mean · ETDRS letter score
LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12
ETDRS letter scorePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Low Luminance VA (LL-VA) Deficit Score in the Study Eye at Month 12-0.76 ± 1.382-2.40 ± 1.424-3.72 ± 1.385
SecondaryLS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12

The foveal encroachment in the study eye was measured by FAF. Baseline is defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) and Month 12.
Reported as:
Least squares mean · mm
LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12
mmPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Distance of GA Lesion From the Fovea (Foveal Encroachment) in the Study Eye at Month 12-0.04 ± 0.011-0.04 ± 0.012-0.06 ± 0.011
SecondaryNumber of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye

The number of subjects with any MNV TEAEs in the study eye was identified via clinical review of all ocular TEAEs.

Time frame:
From the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).
Reported as:
Count of participants · Participants
Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye
ParticipantsPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
Number of Subjects With Any Macular Neovascularization (MNV) TEAEs in the Study Eye1451

Adverse events

Collected over TEAE data is reported from the time of first study drug administration (Day 1) up to Month 12 (Data cut-off date).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan Monthly: Ocular Study Eye0/86 (0%)4/86 (4.7%)51/86 (59.3%)
Pegcetacoplan EOM: Ocular Study Eye0/79 (0%)2/79 (2.5%)35/79 (44.3%)
Sham Pooled: Ocular Study Eye0/81 (0%)1/81 (1.2%)25/81 (30.9%)
Pegcetacoplan Monthly: Ocular Fellow Eye0/86 (0%)0/86 (0%)12/86 (14%)
Pegcetacoplan EOM: Ocular Fellow Eye0/79 (0%)0/79 (0%)8/79 (10.1%)
Sham Pooled: Ocular Fellow Eye0/81 (0%)1/81 (1.2%)10/81 (12.3%)
Pegcetacoplan Monthly: Non-ocular0/86 (0%)12/86 (14%)23/86 (26.7%)
Pegcetacoplan EOM: Non-ocular2/79 (2.5%)23/79 (29.1%)18/79 (22.8%)
Sham Pooled: Non-ocular2/81 (2.5%)16/81 (19.8%)23/81 (28.4%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
Cardiac failure congestiveCardiac disorders0/860/790/810/860/790/814/860/790/81
FallInjury, poisoning and procedural complications0/860/790/810/860/790/810/860/793/81
Atrial fibrillationCardiac disorders0/860/790/810/860/790/812/862/790/81
Multiple organ dysfunction syndromeGeneral disorders0/860/790/810/860/790/810/862/790/81
PneumoniaInfections and infestations0/860/790/810/860/790/812/862/790/81
EndophthalmitisInfections and infestations2/861/790/810/860/790/810/860/790/81
Intraocular pressure increasedInvestigations1/861/790/810/860/790/810/860/790/81
Coronary artery stenosisCardiac disorders0/860/790/810/860/790/810/861/790/81
Inguinal herniaGastrointestinal disorders0/860/790/810/860/790/810/861/790/81
Peptic ulcerGastrointestinal disorders0/860/790/810/860/790/810/861/790/81
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
Vitreous floatersEye disorders19/867/791/814/862/791/810/860/790/81
Conjunctival haemorrhageEye disorders16/869/798/812/860/790/810/860/790/81
Eye painEye disorders12/863/796/811/861/791/810/860/790/81
Neovascular age-related macular degenerationEye disorders10/865/791/812/860/790/810/860/790/81
Visual impairmentEye disorders4/869/793/813/864/792/810/860/790/81
Urinary tract infectionInfections and infestations0/860/790/810/860/790/819/869/797/81
Intraocular pressure increasedInvestigations7/868/790/810/861/791/810/860/790/81
Viral upper respiratory tract infectionInfections and infestations0/860/790/810/860/790/812/863/798/81
FallInjury, poisoning and procedural complications0/860/790/810/860/790/817/862/792/81
HypertensionVascular disorders0/860/790/810/860/790/814/866/796/81

Baseline characteristics

The Intent to Treat (ITT) population included all randomized subjects who received at least one injection of study drug.

Age, Continuous
Age, Continuous(years)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean79.6 ± 7.5181.0 ± 7.5578.4 ± 7.4379.7 ± 7.54
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Female555049154
Male31293292
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
American Indian or Alaska Native0000
Asian1001
Black or African American1102
Native Hawaiian or Other Pacific Islander0000
White847681241
Other0202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Hispanic or Latino2125
Not Hispanic or Latino817677234
Not Reported2002
Unknown1225
Region of Enrollment
Region of Enrollment(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Australia12111235
New Zealand33410
United States716565201
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye(millimeter square (mm^2))Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean8.0 ± 3.848.9 ± 4.478.2 ± 4.058.4 ± 4.12
08

Study locations

46 sites
  • Retina Speciality Institute
    Mobile, Alabama 36606, United States
  • Retinal Research Institute
    Phoenix, Arizona 85014, United States
  • Retina Vitreous Asociates Mdical Goup
    Beverly Hills, California 90211, United States
  • The Gavin Herbert Eye Institute/UC Irvine
    Irvine, California 92697, United States
  • University of Southern California - USC Eye Institute
    Los Angeles, California 90033, United States
  • Byers Eye Institute at Stanford, Stanford School of Medicine
    Palo Alto, California 94303, United States
  • New England Retina Associates
    New London, Connecticut 06320, United States
  • Florida Eye Microsurgical Institute, Inc.
    Boynton Beach, Florida 33426, United States
  • Retina Health Center
    Fort Myers, Florida 33907, United States
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • South East Retina
    Augusta, Georgia 30909, United States
  • Illinois Retina Associates
    Harvey, Illinois 60426, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Elman Research
    Baltimore, Maryland 21237, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Associated Retinal Consultants PC
    Grand Rapids, Michigan 45946, United States
  • Associated Retinal Consultants, PC
    Traverse City, Michigan 49586, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Eyesight Opthalmic Services PA
    Portsmouth, New Hampshire 03801, United States
  • Vitreous Retina Macula Consultants of New York
    New York, New York 10022, United States
  • Charlotte Eye Ear Nose and Throat Associates
    Charlotte, North Carolina 28210, United States
  • Duke University, Duke Eye Center
    Durham, North Carolina 27705, United States
  • Charlotte Eye Ear Nose and Throat Associates
    Statesville, North Carolina 28677, United States
  • Cleveland Clinic Foundation/ Cole Eye Institute
    Cleveland, Ohio 44106, United States
  • Retina Associates of Cleveland
    Cleveland, Ohio 44122, United States
  • Mid Atlantic
    Philadelphia, Pennsylvania 19006, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Research Center
    Austin, Texas 78705, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Valley Retina Institute, PA
    McAllen, Texas 75803, United States
  • Retina Specialists
    Plano, Texas 75093, United States
  • Retina Consultants of Houston (The Woodlands)
    The Woodlands, Texas 77384, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Marsden Eye Specialists
    Paramatta, New South Wales 2150, Australia
  • Save Sight Institute, Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Sydney West Retina
    Westmead, New South Wales 2145, Australia
  • Hobart eye Surgeons
    Hobart, Tasmania 7002, Australia
  • Tasmanian Eye Institute
    South Launceston, Tasmania 7249, Australia
  • Royal Victorian Eye and Ear Hospital
    East Melbourne, Victoria 3002, Australia
  • Center for Eye Research Australia
    Melbourne, Victoria 3002, Australia
  • Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Auckland Eye
    Remuera, Auckland 1050, New Zealand
  • Southern Eye Specialists
    Merivale, Christchurch 8014, New Zealand
09

References and documents

Publications

  • Vogl WD, Riedl S, Mai J, Reiter GS, Lachinov D, Bogunovic H, Schmidt-Erfurth U. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina. 2023 Jan;7(1):4-13. doi: 10.1016/j.oret.2022.08.003. Epub 2022 Aug 7. PubMed 35948209 ↗
  • Liao DS, Metlapally R, Joshi P. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study. Immunotherapy. 2022 Sep;14(13):995-1006. doi: 10.2217/imt-2022-0078. Epub 2022 Jul 21. PubMed 35860926 ↗
  • Nittala MG, Metlapally R, Ip M, Chakravarthy U, Holz FG, Staurenghi G, Waheed N, Velaga SB, Lindenberg S, Karamat A, Koester J, Ribeiro R, Sadda S. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. JAMA Ophthalmol. 2022 Mar 1;140(3):243-249. doi: 10.1001/jamaophthalmol.2021.6067. PubMed 35113137 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jul 2017, 21 months.

Results were first posted in Oct 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2019.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2015
First posted
Jul 20, 2015
StartActual
Sep 24, 2015
Primary completionActual
Jul 14, 2017
CompletionActual
Jan 17, 2018
Results delay requested
Nov 13, 2019
Results first posted
Oct 6, 2020
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02503332
Responsible party
Sponsor
First posted
Jul 20, 2015
Start date
Sep 24, 2015
Primary completion
Jul 14, 2017
Completion
Jan 17, 2018
Results posted
Oct 6, 2020
Last update
Oct 6, 2020

Study contacts

Federico Grossi, MD PhD
study director · Apellis Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion